glaucoma
Conditions
Interventions
three:surgery
Combined surgery group: combining cataract extraction (phacoemulsification plus goniosynechialysis (GSL)) with trabeculectomy (TLE)
trabeculetomy at first stage group:Performing trabeculectomy first and then phacoemulsification
phacoemulsification at first stage group:Performing phacoemulsificationplus GSL at first stage, TLE will be considered if postoperative IOP is uncontrolled meanwhile the eye is in stable condition 3-9
Sponsors
The Eye Hospital of Wenzhou Medical University
Eligibility
Sex/Gender
All
Age
40 Years to 79 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria of CACG are the following: (1) PAS is between 90 and 300 degree; (2) IOP>21 mmHg measured at least 3 times randomly oris controlled(=21mmHg) byat least two medications. (3) GON and correspondingVFdefect: A glaucomatous VFdefect, is defined as a Humphrey automated perimetry result that includes at least three contiguous pointsin the same hemifield on the total deviation probability plot at theless than 5% level (at least 1 plot at theless than 1% level) and a Glaucoma Hemifield Test result that isoutside normal limits. VF abnormalities areconsidered credible if the points are reproducible. Inclusion Criteria of cataractare the following: (1) Patients with the presenceof significant nuclear, cortical, or posterior subcapsular cataract; (2) Corrected visual acuity =0.5 but> 0.1, affecting daily life; Only one eye from each patientcould be recruited. If both eyes of one patient have coexisting CACGand cataract,the eye with much severe diseasewill be included, determined by his surgical doctor.
Exclusion criteria
Exclusion criteria: (1) Refuse to sign written informed consent, or unwilling to acceptrandomized assignment, or difficult to complete the follow-up; (2) Patients own single eye,or the corrected visual acuity of the fellow eye< 0.05; (3) Previous intraocular surgery (other thanLPIorLPIP); (4) Secondary angle closure glaucoma, such as lens dislocation, uveitis, trauma, and neovascular glaucoma. (5) Coexist with other eye diseases, including corneal abnormalities, pathological myopia, uveitis, ocular trauma, fundus lesions (such asdiabetic retinopathy); (6) Patients are enrolled in other clinical trialssimultaneously; (7) Patients suffering from serious systemic diseases can't tolerate any surgery or follow-up. (8) Previously diagnosed acute angle closure attack inthe eligible eye; (9) Axial length=19 mm (nanophthalmos); (10) Corneal endothelial density<1200/mm2.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| intraocular pressure;NEI-VFQ 25;visual field; | — |
Secondary
| Measure | Time frame |
|---|---|
| morphology of filtration bleb;thickness of retinal nerve fiber;cost; | — |
Countries
China
Contacts
Public ContactYuanbo Liang
The eye hospital of Wenzhou medical university
Outcome results
None listed